Aurinia Pharmaceuticals

$14.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (+1.39%) Today
+$0.17 (+1.17%) As of 11:31 PM UTC after-hours

Why Robinhood?

You can buy or sell AUPH and other stocks, options, and ETFs commission-free!

About AUPH

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada. The listed name for AUPH is Aurinia Pharmaceuticals Inc Ordinary Shares.

CEO
Peter S. Greenleaf
Employees
62
Headquarters
Victoria, British Columbia
Founded
1993
Market Cap
1.93B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.76M
High Today
$14.73
Low Today
$14.28
Open Price
$14.52
Volume
3.42M
52 Week High
$20.50
52 Week Low
$9.83

AUPH News

BenzingaFeb 23

Earnings Preview: Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (NASDAQ:AUPH) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for thi

AUPH Earnings

-$0.29
-$0.19
-$0.10
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.14 per share
Actual
-$0.05 per share
Replay Earnings Call

You May Also Like

JFIN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure